David-Alexandre C. Gros - Nov 21, 2024 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role: Chief Executive Officer, Director
Signature: /s/ Paul Little, as attorney-in-fact for David-Alexandre C. Gros, M.D.
Stock symbol: ELDN
Transactions as of: Nov 21, 2024
Transactions value $: $0
Form type: 4
Date filed: 11/22/2024, 05:00 PM
Previous filing: Jun 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELDN	Stock Option (right to buy)	Award	$0	+1.02M		$0.00	1.02M	Nov 21, 2024	Common Stock	1.02M	$2.30	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 1,015,743 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 380,904 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 634,839 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Content

This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 1,015,743 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 380,904 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 634,839 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.